Prolonged exposure to acetaminophen reduces testosterone production by the human fetal testis in a xenograft model by van den Driesche, Sander et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prolonged exposure to acetaminophen reduces testosterone
production by the human fetal testis in a xenograft model
Citation for published version:
Van Den Driesche, S, Macdonald, J, Anderson, RA, Johnston, ZC, Chetty, T, Smith, LB, Mckinnell, C,
Dean, A, Homer, NZ, Jorgensen, A, Camacho-moll, ME, Sharpe, RM & Mitchell, RT 2015, 'Prolonged
exposure to acetaminophen reduces testosterone production by the human fetal testis in a xenograft model'
Science translational medicine, vol. 7, no. 288, pp. 288ra80-288ra80. DOI: 10.1126/scitranslmed.aaa4097
Digital Object Identifier (DOI):
10.1126/scitranslmed.aaa4097
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Science translational medicine
Publisher Rights Statement:
This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for
redistribution. The definitive version was published at http://stm.sciencemag.org/content/7/288/288ra80
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
1 
Prolonged exposure to acetaminophen reduces testosterone production by the human 1 
fetal testis in a xenograft model 2 
 3 
Sander van den Driesche
1#
, Joni Macdonald
1#
, Richard A. Anderson
1
, Zoe C. Johnston
1
, Tarini Chetty 
2
, Lee B. 4 
Smith
1
, Chris Mckinnell
1
, Afshan Dean
1
, Natalie Z. Homer
3
, Anne Jorgensen1,4, Maria-Elena Camacho-Moll
1
, 5 
Richard M. Sharpe
1
, Rod T. Mitchell
1,2*
 6 
 7 
1 MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, 8 
Edinburgh, EH16 4TJ, Scotland, UK. 9 
2 Edinburgh Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, EH9 1LF, Scotland, UK 10 
3 Edinburgh CRF Mass Spectrometry Core, Centre for Cardiovascular Science, The University of Edinburgh, The Queen's Medical Research 11 
Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, Scotland, UK 12 
4 University Department of Growth and Reproduction, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark 13 
 14 
# Both authors contributed equally to the study 15 
 16 
 17 
One Sentence Summary 18 
Prolonged exposure to therapeutic doses of acetaminophen reduces testosterone production by human fetal testis 19 
xenografts. 20 
 21 
Keywords 22 
Fetal testis, testosterone, acetaminophen, steroidogenesis, xenograft  23 
 24 
Correspondence and reprint requests 25 
 2 
*Rod Mitchell, MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical 26 
Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK. Tel: 44 131 242 6470. FAX: 27 
44 131 242 6197. e-mail: rod.mitchell@ed.ac.uk 28 
Abstract 29 
 30 
Most common male reproductive disorders are linked to lower testosterone exposure in fetal life, although the 31 
factors responsible for suppressing fetal testosterone remain largely unknown. Protracted use of acetaminophen 32 
during pregnancy is associated with increased risk of cryptorchidism in sons, but effects on fetal testosterone 33 
production have not been demonstrated. We used a validated xenograft model to expose human fetal testes to 34 
clinically relevant doses and regimens of acetaminophen. Exposure to a therapeutic dose of acetaminophen for 7 35 
days significantly reduced plasma testosterone (45% reduction; p=0.025) and seminal vesicle weight (a biomarker 36 
of androgen exposure; 18% reduction; p=0.005) in castrate host mice bearing human fetal testis xenografts, 37 
whereas acetaminophen exposure for just 1 day did not alter either parameter. Plasma acetaminophen 38 
concentrations (at 1 hour after the final dose) in exposed host mice were substantially below those reported in 39 
humans after a therapeutic oral dose. Subsequent in utero exposure studies in rats indicated that the 40 
acetaminophen-induced reduction in testosterone likely results from reduced expression of key steroidogenic 41 
enzymes (Cyp11a1, Cyp17a1). Our results suggest that protracted use of acetaminophen (1 week) may suppress 42 
fetal testosterone production, which could have adverse consequences. Further studies are required to establish the 43 
dose-response and treatment-duration relationships to delineate the maximum dose and treatment period without 44 
this adverse effect. 45 
46 
 3 
Introduction 47 
 48 
Male reproductive disorders that manifest at birth (cryptorchidism, hypospadias) or in young adulthood (low sperm 49 
counts, testicular germ cell cancer) are remarkably common and their incidence may be increasing (1, 2). A major 50 
cause of these disorders is believed to be deficiency in testosterone production during a critical period of fetal life 51 
(3, 4). However, the factors that might reduce testosterone production or action during fetal life and account for the 52 
high prevalence of these disorders are unknown, although it is likely that lifestyle and environmental factors are 53 
important (5).  54 
 55 
Acetaminophen is the most commonly used analgesic worldwide, and it is available over the counter in most 56 
countries. In the US, more than 65% of pregnant women use acetaminophen at some stage during their pregnancy 57 
(6). Maternal use of acetaminophen and subsequent cryptorchidism in male offspring have been linked in several 58 
human studies, and experimental investigations in rodents indicate this could be due to reduced testicular hormone 59 
production (7-11). 60 
 61 
The aim of the present study was to determine if exposure to a therapeutic dose and regimen of acetaminophen 62 
would result in a reduction in testosterone production by the human fetal testis and to identify potential targets in 63 
the steroidogenic pathway that may result in reducing testosterone, hence providing a mechanistic link between 64 
maternal use of acetaminophen and the occurrence of cryptorchidism and other potential effects in male offspring. 65 
Direct identification of the effect of acetaminophen exposure by evaluating testosterone production by the human 66 
fetal testis in situ is challenging, and use of animal models may not reliably reflect the effects of exposures in 67 
humans (12-14). Use of in vitro cultures of human fetal testis is feasible, but has limitations and does not always 68 
result in the same effects that occur after in utero exposure (15). We have thus developed and validated a xenograft 69 
model of human fetal testicular development, which reflects physiological development and can be used to test the 70 
effects of chemical exposures on testosterone production (12, 16). We used this approach for the present studies. 71 
 72 
 4 
Results 73 
 74 
Xenograft survival and host animal health after exposure to acetaminophen 75 
We transplanted a total of 324 fragments of human fetal testis (n=14) tissue into 64 castrated, hCG-treated host 76 
mice. Mice were exposed to acetaminophen or vehicle according to three different regimens. Overall graft survival 77 
at the end of the experiment was 65%, which is similar to previous studies using this model (12, 16, 17), with no 78 
significant differences in graft retrieval rates between treatments or treatment regimens (Table S1). No significant 79 
differences in total recovered graft weight were seen between vehicle- and acetaminophen-exposed hosts or 80 
between the different treatment regimens (Table S1). Host animals remained healthy, with no significant 81 
differences in body weight between vehicle- and acetaminophen-exposed hosts (Table S1). Histological analysis of 82 
the xenografts revealed preservation of seminiferous cords and interstitial compartments, with similar appearance 83 
between the vehicle- and acetaminophen-exposed xenografts (Fig. 1A). 84 
 85 
Effect of prolonged exposure of human fetal testis xenografts to high-dose acetaminophen  86 
Our initial experiments investigated the effect of exposure to a single high dose (350 mg/kg) of acetaminophen 87 
administered orally daily for 7 days (Fig. 1B), using a regimen previously shown to reduce testosterone production 88 
in the rat fetal testis (350 mg/kg, once daily; (9)). We evaluated the effect of this treatment on xenograft 89 
testosterone production in two independent ways in the host mice when they were sacrificed 1 hour after the final 90 
treatment. We directly measured host plasma testosterone, and we also measured host seminal vesicle (SV) weight, 91 
which is a well-established biomarker of androgen exposure in rodents (3). Although treatment with this single 92 
daily high dose of acetaminophen did not significantly alter host plasma testosterone concentration 1 hour after the 93 
final dose (vehicle controls vs. acetaminophen: 0.35 vs. 0.29 ng/ml; p=0.469; Fig. 1C,D), it did significantly reduce 94 
(27% reduction) host seminal vesicle weight (controls vs. acetaminophen: 13.38 vs. 9.75 mg, p=0.0002; Fig. 1E,F), 95 
indicating that acetaminophen had reduced overall testosterone production by the xenografts over the duration of 96 
the grafting period.  97 
 98 
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Effect of prolonged exposure of human fetal testis xenografts to human-relevant doses of acetaminophen  99 
Because a single daily dose of 350 mg/kg acetaminophen is not human-relevant, we next tested a treatment regimen 100 
(20 mg/kg, orally, 3 times daily for 7 days; Fig. 2A) comparable to that recommended for use in humans. Using this 101 
regimen, plasma concentrations of acetaminophen (1 hour after the final dose) were 0·74 ± 0·07 µg/ml (Fig. 2B), 102 
which is substantially lower than concentrations reported in the serum of normal pregnant women (20.8 µg/ml) 0.8 103 
hours  after a therapeutic dose of acetaminophen (Fig. 2B; (18)). As expected, acetaminophen was undetectable 104 
(<0·1 µg/ml) in vehicle-exposed host mice (Fig. 2B). Exposure of xenografted mice to this therapeutic dose and 105 
regimen of acetaminophen for 7 days resulted in a significant reduction in both host plasma testosterone (45%; 2.49 106 
v. 1.37 ng/ml; p=0·025; Fig. 2C,D) and seminal vesicle weight (18%; 7.83 vs. 6.42mg; p=0·005; Fig. 2E,F), 107 
compared to vehicle-exposed xenografted controls. 108 
  109 
Effect of short-term exposure of human fetal testis xenografts to human-relevant doses of acetaminophen  110 
It is assumed that the majority of pregnant women who use acetaminophen do so for a short period of time, so we 111 
investigated the effect of a single day’s exposure to a therapeutic regimen of acetaminophen (20 mg/kg, orally, 112 
three times daily; Fig. 3A), with measurement of plasma testosterone and seminal vesicle weight 1 hour after the 113 
final acetaminophen dose. Host mouse plasma acetaminophen concentration was 0·94 ± 0·27 µg/ml in 114 
acetaminophen-exposed hosts and was undetectable in vehicle-exposed xenografted controls (Fig. 3B). There was 115 
no difference (p>0·05) in plasma testosterone (Fig. 3C,D) or seminal vesicle weight (Fig. 3E,F) in acetaminophen-116 
exposed host mice compared to vehicle-exposed controls after this single day of treatment. 117 
  118 
Effect of acetaminophen exposure on steroidogenesis in the rat fetal testis 119 
Investigation of the mechanisms responsible for the acetaminophen-induced reduction in testosterone production by 120 
human fetal testis xenografts is technically challenging due to variation in cellular composition of xenografts which 121 
would result in a requirement for a large number of additional fetuses in order to make valid quantitative 122 
assessment of steroidogenic enzyme expression. This would be impractical due to limited tissue availability. We 123 
therefore used the rat as a model, because we have established the critical period when any reduction in fetal 124 
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intratesticular testosterone (ITT) can result in a subsequent male reproductive disorder (2, 3). Treatment of pregnant 125 
rats with the same therapeutic regimen and dose of acetaminophen as used in the human  xenograft studies did not 126 
result in any significant suppression of ITT (Fig. S1), so we used the higher dose (350 mg/kg, administered once 127 
daily from e13.5; Fig. 4A) because this had been shown to be effective in reducing testosterone production in the 128 
fetal rat testis (9). This dose, which resulted in mean blood acetaminophen levels of 44 µg/ml, did not adversely 129 
affect growth of the mothers or pups, indeed there was evidence for a positive effect of acetaminophen on the 130 
weights of both mothers and pups, although the effect on pup weight was not significant if litter bodyweight means 131 
were used (Fig. S2).  Exposure to acetaminophen significantly suppressed ITT (37% reduction; p=0.024) in male 132 
pups at e17.5 (the middle of the masculinization programming window, MPW; (3)) 24 hours after the final dose 133 
(Fig. 4B), although at 3 hours after dosing the treatment-induced decrease in ITT was not significant (p=0.098, Fig. 134 
4C). Independent confirmation that this acetaminophen treatment regimen had induced a biologically relevant 135 
decrease in ITT was provided by a significant reduction (p<0.0001; Fig. 4D) in anogenital index (AGI; calculated 136 
by dividing AGD by the cube root of body weight) at e21.5 in acetaminophen-exposed fetuses, because this 137 
measure provides a biomarker of fetal androgen exposure during the MPW (3). To investigate the mechanism for 138 
acetaminophen-induced reduction in ITT in rat fetuses, we determined the expression of mRNA of key enzymes in 139 
the steroidogenic pathway. Expression of Cyp11a1 (p=0.013; Fig. 5A) and Cyp17a1 (p=0.025; Fig. 5B) were both 140 
significantly reduced 3 hours after the final dose in acetaminophen-exposed, compared with vehicle-exposed, rat 141 
fetal testes, whilst expression of StAR and Hsd3b1 was unchanged (Fig. 5C,D). Expression of Insl3 and Sox-9 142 
mRNAs (relevant to testicular descent and Sertoli cells, respectively) were also unchanged in acetaminophen-143 
exposed, compared with vehicle-exposed, rat fetal testes. To determine whether the reduction in Cyp11a1 and 144 
Cyp17a1 was due to a reduction in the number of Leydig cells, quantification of the Leydig to Sertoli cell ratio 145 
(LC:SC) and number of Leydig cells per area (mm
2
) was performed on vehicle- and acetaminophen-exposed 146 
sections co-stained for 3-HSD and Sox-9 (Fig. 6A,B). There was no significant difference in LC:SC (p=0.437; 147 
Fig. 6C) or in LC/mm
3
 (p=0.465; Fig. 6D) in acetaminophen-exposed compared to vehicle-exposed rat testes. 148 
149 
 7 
Discussion 150 
 151 
The present study demonstrates that exposure to acetaminophen in a therapeutic regimen for 7 days reduces 152 
testosterone production by the xenografted human fetal testis, an effect that occurs in a context engineered to 153 
simulate the normal endocrine environment of the fetal testis (the presence of hCG to stimulate/maintain 154 
steroidogenesis) (19). These results have clinical importance for two reasons. First, acetaminophen is used by the 155 
majority of pregnant women (6). Second, there is growing evidence that most common male reproductive disorders, 156 
which can affect up to 1 in 6 males, may be attributed to suboptimal androgen exposure during fetal life (4), a 157 
parameter which we presently show can be affected by exposure of the fetal human testis to therapeutically-relevant 158 
doses of acetaminophen. This is independently supported by several epidemiological studies, which have shown 159 
that protracted maternal use of acetaminophen is associated with increased risk of cryptorchidism in the exposed 160 
offspring (7-11), and reduced fetal androgen exposure is an established cause of cryptorchidism (3, 4). Moreover, it 161 
has recently been shown that deficiency in fetal testosterone might also result in compromised adult testosterone 162 
production, which has potential implications for more general health consequences (20). 163 
 164 
In the present study, exposure to a high dose (350 mg/kg, once daily) of acetaminophen for 7 days resulted in a 165 
reduction in weight of the androgen-dependent seminal vesicles in host mice, indicating a reduction in testosterone 166 
production by the human fetal testis xenografts over the duration of the exposure. However, the plasma testosterone 167 
measured 1 hour after the final dose showed a non-significant reduction. This may be related to the single daily 168 
dosing schedule. This concept is supported by two further findings from the present study. First, in rats exposed in 169 
utero to an equivalent high dose regimen administered once daily, the reduction in ITT had not occurred by 3 hours 170 
after the final dose, although there was a reduction when ITT was measured 24 hours after the final dose. Second, 171 
we demonstrated a reduction (measured 1 hour after the final dose) in testosterone in xenografted host mice after a 172 
three times daily (for 7 days) therapeutic dosing regimen of a substantially lower acetaminophen dose.  173 
 174 
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The present studies show that a therapeutic acetaminophen regimen (20 mg/kg, three times daily) for 7 days results 175 
in a 45% reduction in testosterone production by human fetal testis xenografts, with a reduction (18%) in SV 176 
weight in host animals. This reduction was evident despite the concomitant presence of physiological stimulation of 177 
testosterone production by hCG (to mimic the human in utero environment), administered to the host mice, which 178 
has been shown to increase testosterone production by human fetal testis xenografts (16). However, exposure to the 179 
same acetaminophen dosing regimen for a single day did not result in a reduction in testosterone or SV weight. This 180 
suggests, at least in this model system, that it is only protracted acetaminophen exposure that suppresses 181 
testosterone production.   182 
 183 
To confirm the potential human health relevance of our findings, we measured plasma acetaminophen 184 
concentrations in host mice, and found concentrations of 0.74-0.94 µg/ml at 1 hour after a dose (therapeutic 185 
regimen). This is well below the concentrations reported in adult humans (6 µg/ml) at the same time-point (1 hour) 186 
after the equivalent oral dose, and using the same type of assay (LC/MS) as the present study (21). In addition, a 187 
study that investigated pregnant and non-pregnant women demonstrated a maximum serum concentration at 0.8 h 188 
after a dose of 20.8 µg/ml during pregnancy and 23.7 µg/ml in the non-pregnant state (18). The reason for the 189 
difference between the acetaminophen concentrations described in the two previous studies is unclear but may 190 
relate, at least in part, to the type of assay used. Acetaminophen passes readily across the placenta, with no 191 
difference in blood concentrations between mother and fetus after an oral therapeutic dose (1g) (22), thus our 192 
results suggest that the testis xenografts in our studies were exposed to concentrations of acetaminophen that are not 193 
higher, and indeed substantially lower, than those likely to occur in the human fetus after maternal use of a standard 194 
therapeutic dose. Previous in vitro studies have shown that acetaminophen can reduce testosterone production in the 195 
rat fetal testis, demonstrating a direct effect not mediated by metabolites (9). These considerations indicate that the 196 
present findings might therefore underestimate the effects of acetaminophen exposure in humans, if the effect of 197 
acetaminophen on testosterone production by xenografts is dose-dependent. In this regard, it also appears that the 198 
human fetal testis may be more sensitive to the adverse steroidogenic effects of acetaminophen than the fetal rat 199 
 9 
testis, as evidenced by our failure to detect any significant steroidogenic effect of a therapeutic dosing regimen in 200 
rats.  201 
 202 
A limitation of our study is that the xenograft model may not accurately reflect the in utero situation for humans. 203 
However, it is not possible to test directly the effects of acetaminophen on fetal testis testosterone production in 204 
pregnant women. Our xenograft system has been shown to model normal human fetal testis development, including 205 
its steroidogenic function (16, 23), and previous studies have demonstrated its validity as a model to assess the 206 
effects of potential endocrine disruptors on testosterone production. These studies have shown consistency of 207 
results in the xenograft system with those of in vitro studies in the human fetal testis and in vivo studies in non-208 
human primates (12, 13, 15, 24, 25) . This includes studies that utilise exposures to known inhibitors of 209 
steroidogenesis (23), or fetal testis tissue xenografts from species where exposure is known to reduce testosterone 210 
in vivo (12, 13), as positive controls. Therefore we consider the xenograft model to be a dynamic and reliable model 211 
with which to investigate the effects of chemical and drug exposures on steroidogenesis (12). Our present results 212 
contrast with a study that investigated the effects of acetaminophen exposure on first trimester (8-12 weeks 213 
gestation) human fetal testes in vitro, and found no effect on testosterone production after 24-72 hours of culture 214 
(26). This discrepancy could indicate differential effects of acetaminophen exposure in first trimester compared 215 
with the second trimester human fetal testes used in this study. However, it is perhaps more likely that the lack of 216 
effect of acetaminophen on testosterone production in vitro may relate to inconsistent effects on steroidogenesis 217 
that have been shown to occur when compared to the in utero response (15), and these differential effects may be 218 
dependent on the specific culture conditions (27).  219 
 220 
To provide mechanistic support for our findings in an in utero model, we exposed pregnant rats to acetaminophen 221 
using two different regimens. We demonstrated that once daily exposure to acetaminophen from e13.5 resulted in a 222 
reduction in ITT 24 hours after the final dose at e17.5. This was associated with a reduction in AGI at e21.5, which 223 
is an established indicator of fetal androgen exposure (4). Similar effects on AGI after acetaminophen exposure in 224 
fetal rats have been described previously (9). Having demonstrated a reduction in testosterone production, we 225 
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investigated steroidogenic enzyme expression in the rat fetal testis after exposure to acetaminophen. We showed a 226 
significant reduction in both Cyp11a1 and Cyp17a1 mRNA expression 3 hours after the final dose of 227 
acetaminophen. Cyp11a1 catalyzes the conversion of cholesterol to pregnenolone in the gonad and is the rate-228 
limiting enzyme in the steroidogenic pathway (19, 28). We have previously shown in fetal rats that a reduction in 229 
Cyp11a1 mRNA of similar magnitude to that in the present study also results in a reduction in Cyp11a1 protein 230 
expression (29). Cyp17a1 is responsible for catalyzing the conversion of 17-hydroxy-pregnenolone to 231 
dehydroepiandrosterone and is also an important determinant of testosterone production that is subject to regulation 232 
and perturbation (30). To confirm that the reduction in expression of these key steroidogenic enzymes was not due 233 
to a loss of Leydig cells, we showed that mRNA expression of several other Leydig cell products, including 3β-234 
HSD and Insl3, was unchanged by exposure to acetaminophen. Furthermore, we took advantage of the stable 235 
mRNA expression of Hsd3b1 (Leydig cell) and Sox-9 (Sertoli cell) to perform Leydig cell counts, which also 236 
indicated that LC number was unchanged after exposure to acetaminophen, determined by two independent 237 
methods of quantification. Whether the effects of acetaminophen on expression of CYP11a1 and CYP17a1 are 238 
direct or indirect remains to be established. However, these results provide mechanistic support for our findings of 239 
reduced testosterone production by the xenografted human fetal testis after exposure to acetaminophen.  240 
 241 
The present findings provide the beginnings of a mechanistic explanation for the association between protracted 242 
acetaminophen use in human pregnancy and the increased occurrence of cryptorchidism in sons (9, 11), because the 243 
majority of cases of cryptorchidism involve failure of the androgen-dependent phase of testis descent (31, 32). Our 244 
findings might also have relevance in terms of other associated male reproductive disorders, such as hypospadias, 245 
testicular germ cell cancer, and low sperm counts, which are also linked to reduced androgen exposure in utero (4).  246 
 247 
In conclusion, we show that 1 week’s exposure to a human-equivalent therapeutic regimen of acetaminophen 248 
results in reduced testosterone production by xenografted human fetal testis tissue, whilst short-term (1 day) use 249 
does not result in any long-lasting suppression of testosterone production. Because our results are based on the use 250 
of a model system, it is not possible to translate our findings into a categorical recommendation regarding what 251 
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would be safe or unsafe use of acetaminophen by women during pregnancy. However,  a pragmatic approach may 252 
involve the avoidance of protracted use of acetaminophen during pregnancy where possible, a suggestion that is 253 
underscored by the epidemiological data linking protracted acetaminophen use in pregnancy with increased risk of 254 
cryptorchidism in sons (7-9, 11).  255 
256 
 12 
Materials and Methods 257 
 258 
Experimental design 259 
Given the reported association between maternal use of acetaminophen and cryptorchidism, we aimed to 260 
determine whether exposure to acetaminophen reduces testosterone production by the human fetal testis. We 261 
performed a controlled laboratory experiment that used a validated xenograft system to expose human fetal testis 262 
tissue to ‘human-equivalent’ therapeutic doses of acetaminophen administered orally to the immunocompromised 263 
host mice. In addition, studies were also performed in rats to determine the mechanism for acetaminophen’s 264 
effects on fetal testis steroidogenesis. Inclusion criteria and measured endpoints were defined before the start of 265 
the study. For all experiments, the sample sizes for human fetal testes (minimum n=4 for each treatment regimen) 266 
and for rat fetuses (n=3 litters per group) were based on those required to achieve statistical significance in 267 
previous studies using the same methodology (12, 17). The study was stopped once the required number of 268 
experiments had been conducted, and data were analyzed after the cessation of the study. No outliers were 269 
excluded. To compare the effects of treatment versus vehicle for each individual human fetal testis, we grafted 270 
tissue from each fetus into 3-6 replicate host mice and randomly allocated these to receive either acetaminophen or 271 
vehicle treatment. The endpoints included measurement of seminal vesicle (SV) weight and plasma testosterone in 272 
host mice bearing testis tissue xenografts. Seminal vesicles were weighed by a single investigator and verified by 273 
a second investigator who was blinded to the treatment group. Blood was taken from host mice, and plasma was 274 
extracted for analysis of testosterone and acetaminophen using validated assays with 3 replicates per sample.  One 275 
host mouse was excluded from analysis because of incomplete castration. For the rat studies, pregnant dams were 276 
randomly allocated to receive either acetaminophen or vehicle via oral administration. The investigators 277 
performing the blood sample, ITT, and steroidogenic enzyme analysis were blinded to the treatment group.  278 
 279 
Ethics statement 280 
Human fetal testes were obtained after elective termination of pregnancy, according to the Declaration of Helsinki 281 
- Ethical Principles for Medical Research Involving Human Subjects. Ethical approval for the study was obtained 282 
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from the South-East Scotland Research Ethics Committee (Reference number - LREC08/S1101/1). Women gave 283 
written informed consent. Animal studies received specific approval by the UK Home Office, including ethical 284 
approval, and were performed according to the Animal (Scientific Procedures) Act 1986.  285 
 286 
Human xenografting studies 287 
Animals 288 
For xenografting studies, male CD1 nude (host) mice (aged 4-6 weeks; n=64; Charles River UK) were 289 
anesthetised by inhalation of isoflurane and castrated through a scrotal incision. Castration was performed at least 290 
2 weeks before xenografting. After castration, mice received analgesia (Carprofen; Pfizer) in the drinking water 291 
for 3 days.  292 
 293 
Human tissue and xenografting procedure 294 
Human fetal testes (n=14; 14 weeks n=3, 15 weeks n=6, 16 weeks n=1, 17 weeks n=3, 20 weeks n=1) were grafted 295 
into castrate host mice as previously described (16). Briefly, a small portion of each testis was immediately fixed as 296 
a pre-graft control, whilst the remainder was placed immediately into ice-cold medium containing Liebowitz L-15 297 
with glutamine, 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% non-essential amino acids (all Sigma 298 
Aldrich) for xenografting. Small pieces (1 mm
3
 approx.) of testis tissue were inserted subcutaneously under the 299 
dorsal skin of the mice using a 13G cancer implant needle (Popper and Sons). Grafts (4-6 per mouse) were inserted 300 
on either side of the midline. In general, 3-6 mice were xenografted with tissue from each fetus, and mice were 301 
maintained for 7 days to allow grafts to establish a blood supply before any host treatments commenced. 302 
 303 
Treatments 304 
 14 
One week after grafting, host mice commenced treatment with subcutaneous injection of human chorionic 305 
gonadotropin (20 IU hCG every 72 hours; Pregnyl, Organon Laboratories) to mimic the human in utero 306 
environment (16). Host mice were also randomly allocated to receive either acetaminophen or vehicle (corn oil) by 307 
daily oral administration according to one of the following regimens: 308 
 309 
1) High dose 7 day - 350 mg/kg, once daily for 7 days with analysis 1 hour after the final dose 310 
2) Therapeutic dose 7 day - 20 mg/kg, three times daily for 7 days with analysis 1 hour after the final dose 311 
3) Therapeutic dose 1 day - 20 mg/kg, three times daily for 1 day with analysis 1 hour after the final dose 312 
 313 
Xenograft retrieval 314 
Host mice were sacrificed by cervical dislocation, and blood was obtained by cardiac puncture for assessment of 315 
plasma testosterone and acetaminophen. Testosterone production and action was assessed by measuring plasma 316 
testosterone and seminal vesicle weight (16). Xenografts were retrieved and weighed prior to fixation in Bouins 317 
Fluid (Clin-Tech). Fixed sections were stained with Hematoxylin and Eosin (H+E). 318 
 319 
Testosterone assay 320 
Plasma testosterone levels in xenografted hosts were measured at termination by competitive radioimmunoassay 321 
using an extraction-based in-house radioimmunoassay method described previously (33). Testosterone levels were 322 
expressed as ng/ml (human xenografts). All samples were analysed in a single assay with 3 replicates. The 323 
detection limit was 45 pg/ml and the intra-assay CV 8%. 324 
 325 
Acetaminophen assay 326 
Acetaminophen (APAP) was extracted from plasma by liquid-liquid extraction with acidified HPLC-grade 327 
methanol (Fisher Scientific). Briefly, 10 µL plasma was enriched with 10 ng deuterium-labelled acetaminophen 328 
(APAP-d4; Santa Cruz Biotechnology Inc) as internal standard, 0.8 mL methanol (w/ 0.2% acetic acid, Sigma 329 
Aldrich) was added, and the samples were then vortexed and incubated for 20 min on ice. After centrifugation 330 
 15 
(3000 g, 10 min, 10
o
C), the supernatant was reduced to dryness under nitrogen at 40
0
C, reconstituted in mobile 331 
phase (200 µL water/methanol (65:35, v/v), and centrifuged for a second time.  332 
 333 
Chromatographic separation was achieved using an Aria CTC autosampler and Allegros pump on an ACE Excel 2 334 
SuperC18 column (150 x 3 mm; 2 µm) protected by a Kinetex KrudKatcher (Phenomenex) at 20
o
C, and 335 
acetaminophen was detected on a TSQ Quantum Discovery triple quadrupole mass spectrometer (Thermo Fisher 336 
Scientific). The mobile phase consisted of 0.1% formic acid (Sigma Aldrich) in water and 0.1% formic acid in 337 
methanol (B) at a flow rate of 0.3 mL/min. Gradient elution was achieved with a total run time of 9 min from 35% 338 
to 5% B. APAP eluted at 3.95 mins. The mass spectrometer was operated in positive ion electrospray mode 339 
(300
o
C, 3 kV). Transitions monitored were m/z 152  110 and m/z 156.1  114.1 for APAP and APAP-d4, 340 
respectively. 341 
 342 
Rat in utero exposure studies 343 
Animals and treatments 344 
Wistar rats were maintained according to UK Home Office guidelines and were fed a soy-free breeding diet 345 
(RM3(E) soya free; SDS). Housing conditions were carefully controlled (lights on at 0700, off at 1900 h, 346 
temperature 19–21°C, GOLD shavings and LITASPEN standard bedding (SPPS). Time-mated female rats were 347 
subjected to once daily treatment with either acetaminophen (high dose - 350 mg/kg/d; therapeutic dose – 20 348 
mg/kg three times daily, in corn oil) or vehicle (corn oil) by oral gavage commencing at e13.5, with measurement 349 
of ITT at e17.5 (3 hours or 24 hours after the final dose) and AGI at e21.5. 350 
 351 
To acquire fetal samples, rat dams were sacrificed by inhalation of CO2 followed by cervical dislocation. Fetuses 352 
were removed, decapitated, and placed in ice-cold phosphate buffered solution (PBS; Sigma-Aldrich). Fetal 353 
anogenital distance (AGD) was measured in males between the base of the phallus and the anterior margin of the 354 
anus using digital calipers (Faithfull Tools). AGI was calculated by dividing AGD by the cube root of body 355 
weight. From each fetus, one testis was microdissected, snap frozen, and stored at -70
o
C for determination of ITT 356 
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or for gene expression analysis. For ITT, testis tissue was placed in tubes containing Phosphate Buffered Saline 357 
(PBS) and a metal bead (Qiagen) and homogenized using two cycles with the tissue lyser (Qiagen). Total 358 
testosterone content of the lysate was measured using a validated radioimmunoassay as described above. The 359 
remaining testis was immediately placed in Bouins fluid for 1 hour followed by transfer to 70% ethanol.  Fixed 360 
testes were embedded in paraffin using standard processes, and sections of 5 µm thickness were prepared for 361 
subsequent immunofluorescence.  362 
 363 
Double immunofluorescence for Sox-9 and 3β-HSD in fetal rat testis 364 
In order to facilitate analysis of different cell populations, specific antibodies were used for co-365 
immunolocalization of the Sertoli cell marker Sox-9 and the Leydig cell marker 3β-HSD. Sections (5 μm) were 366 
dewaxed in xylene and rehydrated in a graded ethanol series, followed by incubation for 30 min at room 367 
temperature (RT) in 3% (v/v) H2O2 in methanol in order to block endogenous peroxidase. Sections were then 368 
washed twice (5 min each) in TBS. All subsequent incubations were carried out in a humidity box (Thermo Fisher 369 
Scientific) at RT unless otherwise stated, and washes between incubation steps were in TBS (2 x 5 min). To block 370 
non-specific binding, sections were incubated for 30 min in normal chicken serum (NCS; Biosera) diluted 1:5 in 371 
TBS containing 5% (w/v) Bovine Serum Albumin (NCS/TBS/BSA), followed by incubation overnight at 4°C 372 
with anti-Sox-9 antibody (Merck Millipore) diluted 1:6000 in NCS/TBS/BSA. Sections were then incubated for 373 
30 minutes with peroxidase-conjugated chicken anti-rabbit secondary antibody (DAKO), diluted 1:200 in 374 
NCS/TBS/BSA, followed by incubation for 10 min with tyramide (TSA-Plus Cyanine3 System; Perkin Elmer Life 375 
Sciences) according to the manufacturer's instructions. Sections were then subjected to antigen retrieval by boiling 376 
in a pressure cooker in 0.01 M citrate buffer (pH 6.0) for 5 min and left to cool for 20 min, followed by blocking 377 
for 30 min in NCS/TBS/BSA and overnight incubation at 4°C with anti-3β-HSD antibody (Santa Cruz 378 
Biotechnology) diluted 1:200 in NCS/TBS/BSA. Sections were then incubated for 30 min with peroxidase-379 
conjugated chicken anti-goat secondary antibody (Santa Cruz Biotechnology) diluted 1:200 in NCS/TBS/BSA, 380 
followed by incubation for 10 min with tyramide (TSA-Plus Cyanine5 System; Perkin Elmer Life Sciences). 381 
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Sections were mounted with Permafluor (Thermo Fisher Scientific). Fluorescent images of complete testis cross-382 
sections were captured using an LSM 710 Axio Observer Z1 confocal laser microscope (Carl Zeiss Ltd.). 383 
 384 
Quantification of Leydig cells 385 
For quantification of Leydig cells in vehicle- and acetaminophen-exposed testes, the numbers of both Sertoli cells 386 
(SC; Sox-9-positive nuclei), as an internal reference control, and Leydig cells (LC; nuclei associated with 3β-387 
HSD-positive cytoplasm) were quantified using two independent measures, namely, LC:SC and total LC/mm
2
. 388 
We used images of complete fetal rat testes cross-sections (n=4; 2 sections per animal) immunostained for Sox-9 389 
and 3β-HSD as described above. Fluorescent images were examined with ZEN Lite software (Carl Zeiss Ltd), and 390 
the contour tool was used to draw around the testis margin and automatically calculate the cross-section area 391 
(mm
2
). The grid overlay tool was used to facilitate systematic scanning of sections and cell counting. Image-Pro 392 
6.2 with Stereologer plug-in software (MagWorldwide) was used to manually tag/count cells. All SC and LC 393 
nuclei within the sections were counted. For both methods of LC quantification, cell counts from two replicate 394 
sections per fetal testis were aggregated to give total SC and LC counts per animal (1405 +/- 343.2 cells). 395 
 396 
Gene expression analysis  397 
For quantitative analysis of gene expression by RT-PCR, total RNA was extracted from vehicle- and 398 
acetaminophen-exposed rat fetal testes (n=11-12) using the RNeasy Micro Kit with on-column DNase digestion 399 
(Qiagen). Random hexamer primed cDNA was prepared using the Applied Biosystems Taqman RT kit (Applied 400 
Biosystems). Quantitative real time PCR (qRT-PCR) was performed on the ABI Prism Sequence Detection 401 
System (Applied Biosystems). Expression of rat StAR, Cyp11a1, Cyp17a1, Hsd3b1, Insl3, and Sox-9 RNA was 402 
determined using the Roche Universal Probe Library (StAR forward primer: 5’-TCACGTGGCTGCTCAGTATT-403 
3’, reverse primer: 5’-GGGTCTGTGATAAGACTTGGTTG-3’, probe number 83 Cat no. 04689062001; Cyp11a1 404 
forward primer: 5’-TATTCCGCTTTGCCTTTGAG-3’, reverse primer 5’-CACGATCTCCTCCAACATCC-3’, 405 
probe number 9 Cat no. 04685075001; Cyp17a1 forward primer: 5’-CATCCCCCACAAGGCTAAC-3’, reverse 406 
primer: 5’-TGTGTCCTTGGGGACAGTAAA-3’, probe number 67 Cat no. 04688660001; Hsd3b1 forward 407 
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primer: 5’-GACCAGAAACCAAGGAGGAA-3’, reverse primer: 5’-CTGGCACGCTCTCCTCAG-3’, probe 408 
number 105 Cat no. 04692241001); Insl3 forward primer: 5’-TTC CTC ACC AGG CTT CTC AG-3’, reverse 409 
primer: 5'-CAG ACC CAA AAG GTC TTG CT-3', probe number 71 Cat. No. 04688945001; Sox9 forward 410 
primer: 5’-ATC TTC AAG GCG CTG CAA-3’, reverse primer: 5’-CGG TGG ACC CTG AGA TTG-3’, probe 411 
number 63 Cat. No. 04688627001; (Roche Applied Sciences). The expression of each gene was normalized using 412 
a ribosomal 18S internal control (Applied Biosystems Cat no. 4308329). All samples were run in triplicate and 413 
compared to adult testis control cDNA (Ambion).  414 
 415 
Statistical Analysis 416 
For human xenografting studies, results were analysed by two-way ANOVA to account for inter-individual 417 
variation between fetuses, as previously described (12). For each treatment regimen, tissue from each fetus (n=4-5) 418 
was considered an individual experiment. Tissue from each fetus was grafted into 3-6 replicate host mice (4-6 grafts 419 
per mouse), and each mouse was randomly allocated to receive vehicle or acetaminophen. For rat studies, analysis 420 
was performed using unpaired t-tests. P<0.05 was used to determine significance. No outliers were excluded. 421 
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Supplementary Materials 422 
 423 
Table S1 - Xenograft retrieval rates, total graft weight and host mouse body weight following exposure to 424 
acetaminophen 425 
 426 
Figure S1 - Low-dose acetaminophen exposure and intratesticular testosterone in the fetal rat 427 
 428 
Figure S2 – Effect of exposure to acetaminophen on pregnant rats (bodyweight) and their male offspring 429 
(bodyweight/AGD) 430 
431 
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Figure Legends 557 
 558 
Figure 1. High-dose acetaminophen exposure and steroidogenesis by human fetal testis xenografts 559 
A) Histological appearance (H+E staining) of xenografts exposed to vehicle (VEH) and high-dose acetaminophen 560 
(ACET) with corresponding low-power images of whole grafts (inset). Seminiferous cord structure is maintained 561 
during the grafting period. Scale bar – 50 µm. B) High-dose (350 mg/kg, once daily for 7 days) acetaminophen 562 
exposure regimen for human fetal testis xenografts.. Plasma testosterone (C, D) and seminal vesicle weight (E, F) 563 
in host mice (n=12-13 host mice)  bearing human fetal (n=5 total; 15 weeks n=3, 16 weeks n=1, 17 weeks n=1) 564 
testis xenografts after exposure to acetaminophen  (red; ACET) or vehicle  (blue; VEH). Panels D and F show 565 
overall mean data. Graphs show means +/- SEM. Data analyzed by two-way ANOVA. 566 
 567 
Figure 2. Therapeutic acetaminophen exposure and steroidogenesis by human fetal testis xenografts 568 
A) Therapeutic dose (20 mg/kg, three times daily for 7 days) acetaminophen exposure regimen for human fetal 569 
testis xenografts. Plasma acetaminophen (B) and testosterone (C, D) concentrations and seminal vesicle weight (E, 570 
F) in host mice (n=11-12 host mice) bearing human fetal (n=5 total; 14 weeks n=3, 15 weeks n=1, 17 weeks n=1) 571 
testis xenografts after exposure to acetaminophen (red; ACET) or vehicle (blue; VEH). Dashed line in B shows 572 
the mean acetaminophen concentration in humans exposed to an equivalent dose of acetaminophen (21). Panels D 573 
and F show overall mean data. Graphs show means +/- SEM. Data analyzed by two-way ANOVA. 574 
 575 
Figure 3. Short-term therapeutic acetaminophen and steroidogenesis by human fetal testis xenografts 576 
A) Therapeutic dose (20 mg/kg, three times daily for 1 day) acetaminophen exposure regimen for human fetal 577 
testis xenografts. Plasma acetaminophen (B) and testosterone (C, D) concentrations and seminal vesicle weight (E, 578 
F) in host mice (n=8 host mice ) bearing human fetal (n=4 total; 15 weeks n=2, 17 weeks n=1, 20 weeks n=1) 579 
testis xenografts after exposure to acetaminophen (red; ACET) or vehicle (blue; VEH). Dashed line in B shows 580 
the mean acetaminophen concentration in humans exposed to an equivalent dose of acetaminophen (21). Panels D 581 
and F show overall mean data. Graphs show mean +/- SEM. Data analyzed by two-way ANOVA. 582 
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 583 
Figure 4. High-dose acetaminophen exposure and steroidogenesis by the fetal rat testis 584 
A) Schematic for acetaminophen dosing regimens used in pregnant rats. Acetaminophen treatment (350 mg/kg 585 
once daily) commenced at e13.5 and litters were taken at e17.5 for intratesticular testosterone (ITT) measurements 586 
at 24 h (B; n=23-25) and 3 h (C; n=20-24) after the final treatment dose. Anogenital index (AGI), a biomarker of 587 
androgen exposure, was measured at e21.5 (D; n=39-45), after daily treatment from e13.5 with acetaminophen 588 
(ACET; red) or vehicle (VEH; blue). Graphs show mean +/- SEM. Data analyzed by unpaired t-test. 589 
 590 
Figure 5. High-dose acetaminophen exposure and mRNA expression in the rat fetal testis 591 
Treatments commenced at e13.5 and tissue was collected at e17.5, 3 h after the final treatment. Results show 592 
mRNA expression relative to human adult testis cDNA for A) Cyp11a1, B) Cyp17a1, C) Hsd3b1, D) StAR, E) Insl3 593 
and F) Sox9 after acetaminophen (ACET; red) or vehicle (VEH; blue) exposure (n=11-12). Graphs show mean +/- 594 
SEM. Data analyzed by unpaired t-test. 595 
 596 
Figure 6. High-dose acetaminophen exposure and Leydig cell number in the rat fetal testis 597 
Treatments commenced at e13.5 and tissue was collected at e17.5, 3 h after the final treatment. A) Double 598 
immunofluorescence for 3-HSD (Leydig cells; green) and Sox-9 (Sertoli cells; red) in vehicle- (VEH; A) and 599 
acetaminophen- (ACET; B) exposed rat fetal testes. Scale bar – 50 µm.  C) Quantification of Leydig cell to Sertoli 600 
cell ratio (LC:SC) and D) Leydig cells/mm
2
 for acetaminophen (ACET; red) or vehicle (VEH; blue) exposure 601 
(n=4). Graphs show mean +/- SEM. Data analyzed by unpaired t-test. 602 
